Convalescent plasma (CP) from blood donors with anti-SARS-CoV-2 antibodies may benefit patients with COVID-19 by providing immediate passive immunity via transfusion, or when used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), volume of transfusion, and timing of administration remain to be determined. Preliminary safety data for COVID-19 CP are encouraging, but establishing the clinical efficacy of CP requires recruitment of patients to high-quality randomized trials and an ongoing international collaborative effort.

This content is only available as a PDF.

Article PDF first page preview

Article PDF first page preview